Target Name: MIR29B1
NCBI ID: G407024
Review Report on MIR29B1 Target / Biomarker Content of Review Report on MIR29B1 Target / Biomarker
MIR29B1
Other Name(s): mir-29b-1 | miRNA29B1 | hsa-miR-29b-1-5p | miR-29b | hsa-mir-29b-1 | MIRN29B1 | MicroRNA 29b-1 | hsa-miR-29b-3p | microRNA 29b-1

MIR29B1: A Non-Coding RNA Molecule as A Potential Drug Target Or Biomarker

MIR29B1, also known as mir-29b-1, is a non-coding RNA molecule that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed new light on its role in these areas.

MIR29B1 is a microRNA (miRNA), a small non-coding RNA molecule that plays a critical role in post-transcriptional gene regulation. MiRNAs are designed to target specific mRNAs for degradation, and their levels are regulated by various factors, including local interactions with protein partners and interactions with other molecules in the cell.

MIR29B1 has been shown to play a role in various cellular processes, including cell growth, differentiation, and apoptosis. It has been shown to regulate the expression of target genes that are involved in cell signaling pathways, such as the TGF-β pathway, which plays a role in cell growth, differentiation, and survival.

In addition to its role in cell signaling pathways, MIR29B1 has also been shown to have anti-inflammatory effects. Chronic inflammation is a major contributor to various diseases, including neurodegenerative diseases and autoimmune disorders. Therefore, it is important to investigate the role of MIR29B1 in regulating inflammation and its potential as a therapeutic target.

MIR29B1 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of cancer. The TGF-β pathway is a well-established target for cancer, and MIR29B1 has been shown to regulate TGF-β activity, which is involved in the regulation of cell proliferation and survival. Therefore, it is important to investigate the role of MIR29B1 in the regulation of TGF-β activity and its potential as a cancer therapeutic target.

In addition to its potential as a drug target or biomarker, MIR29B1 has also been shown to have potential clinical applications. The TGF-β pathway is involved in the development and progression of many diseases, including cancer, and MIR29B1 has been shown to play a role in regulating TGF-β activity. Therefore, it is important to investigate the potential clinical applications of MIR29B1, including its potential as a therapeutic target for cancer and other diseases.

In conclusion, MIR29B1 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell signaling pathways and the regulation of cellular processes that are important for the development and progression of cancer. Its unique structure and function make it an attractive target for research into its potential as a drug target or biomarker. Further studies are needed to fully understand the role of MIR29B1 in these areas and its potential clinical applications.

Protein Name: MicroRNA 29b-1

The "MIR29B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR29B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059 | MIR3064 | MIR3065 | MIR3074 | MIR3085 | MIR30A | MIR30B | MIR30C1 | MIR30C2 | MIR30D | MIR30E | MIR31 | MIR3115 | MIR3116-1 | MIR3116-2 | MIR3117 | MIR3118-1 | MIR3118-2 | MIR3118-3 | MIR3118-4 | MIR3118-5 | MIR3118-6 | MIR3119-1 | MIR3119-2 | MIR3120 | MIR3121 | MIR3122 | MIR3123 | MIR3124 | MIR3125 | MIR3126 | MIR3127 | MIR3128 | MIR3129 | MIR3130-1 | MIR3130-2 | MIR3131 | MIR3132 | MIR3133 | MIR3134 | MIR3135A | MIR3135B | MIR3136 | MIR3137 | MIR3138 | MIR3139 | MIR3140 | MIR3141 | MIR3142 | MIR3142HG | MIR3143 | MIR3144 | MIR3145 | MIR3146 | MIR3147 | MIR3147HG | MIR3148 | MIR3149 | MIR3150A | MIR3150B | MIR3151 | MIR3152 | MIR3153 | MIR3154 | MIR3155A | MIR3155B | MIR3156-1 | MIR3156-2 | MIR3156-3 | MIR3157 | MIR3158-1 | MIR3158-2 | MIR3159 | MIR3160-1 | MIR3160-2 | MIR3161 | MIR3162 | MIR3163 | MIR3164 | MIR3165 | MIR3166 | MIR3167 | MIR3168 | MIR3169 | MIR3170 | MIR3171 | MIR3171HG | MIR3173